Heparin-induced thrombocytopenia future or investigational therapies
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia future or investigational therapies |
|
FDA on Heparin-induced thrombocytopenia future or investigational therapies |
|
CDC on Heparin-induced thrombocytopenia future or investigational therapies |
|
Heparin-induced thrombocytopenia future or investigational therapies in the news |
|
Blogs on Heparin-induced thrombocytopenia future or investigational therapies |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3]
Overview
Future or Investigational Therapies
Future therapies for HIT focus on use of new oral anticoagulants.[1] Director factor X inhibitors and newer direct thrombin inhibitors are being studied, but the data is currently in its infancy. Cost-effectiveness analyses will need to be done to determine whether it is appropriate to use these new agents.
References
- ↑ Harenberg J, Marx S, Krejczy M, Wehling M (2012). "New anticoagulants - promising and failed developments". Br J Pharmacol. 165 (2): 363–72. doi:10.1111/j.1476-5381.2011.01578.x. PMC 3268190. PMID 21740405.